Bertil Lindmark, new Executive Director R&D in Almirall

Barcelona, 17 January 2011.- Almirall announces the appointment of Dr. Bertil Lindmark as Executive Director R&D after Dr. Per-Olof Andersson’s recently announced retirement. This appointment strengthens Almirall’s R&D team in areas that are of particular interest to the company.

Dr. Lindmark brings to the position 20 years’ experience in pharmaceutical R&D with a focus on respiratory. Bertil also has extensive training in gastric diseases as he is Board Certified in Internal Medicine and Gastroenterology from the University of Lund (Sweden). He obtained his MD degree and PhD in Molecular Epidemiology from the same university.

His professional career includes serving as Vice President and Head of Clinical Development for AstraZeneca in Japan, prior to which he was Global Vice President for the Clinical Respiratory & Inflammation Therapeutic Area also for the said company.

About Almirall Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.   

Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatological conditions.

Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.

For further information please visit the website at: www.almirall.com

More information: Ketchum Pleon:  Sonia San Segundo / Victorino Ballestero sonia.sansegundo@ketchumpleon.com Tel.: 91 788 32 00